retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Retatrutide, the triple-G (GLP-1, GIP, and receptor) caused patients with and knee osteoarthritis to lose an average of 23.7% of body weight after 68 weeks, according to the results Medscape | The investigational triple
Pay in 4 interest-free payments of $6.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10



























